Naruedon Phusi
Overview
Explore the profile of Naruedon Phusi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pakamwong B, Thongdee P, Kamsri B, Phusi N, Taveepanich S, Chayajarus K, et al.
J Chem Inf Model
. 2024 Jul;
64(15):5991-6002.
PMID: 38993154
is the single most important global infectious disease killer and a World Health Organization critical priority pathogen for development of new antimicrobials. DNA gyrase is a validated target for anti-TB...
2.
Thongdee P, Nagura Y, Sabishiro H, Phusi N, Sukchit D, Kamsri P, et al.
J Biomol Struct Dyn
. 2023 Dec;
43(3):1192-1205.
PMID: 38063158
Tuberculosis (TB), the second leading infectious killer, causes serious public health problems worldwide. To develop novel anti-TB agents, many biochemical studies have targeted the subunit B of DNA gyrase (GyrB),...
3.
Pornprom T, Phusi N, Thongdee P, Pakamwong B, Sangswan J, Kamsri P, et al.
Talanta
. 2023 Sep;
267:125210.
PMID: 37717539
Tuberculosis (TB) currently remains a major life-threatening disease as it can be fatal if not treated properly or in a timely manner. Herein, we first describe a disposable and cost-effective...
4.
Kamsri B, Pakamwong B, Thongdee P, Phusi N, Kamsri P, Punkvang A, et al.
J Chem Inf Model
. 2023 Apr;
63(9):2707-2718.
PMID: 37074047
Mutations in DNA gyrase confer resistance to fluoroquinolones, second-line antibiotics for infections. Identification of new agents that inhibit DNA gyrase ATPase activity is one strategy to overcome this. Here, bioisosteric...
5.
Phusi N, Hashimoto Y, Otsubo N, Imai K, Thongdee P, Sukchit D, et al.
Comput Biol Med
. 2022 Dec;
152:106434.
PMID: 36543008
2-trans enoyl-acyl carrier protein reductase (InhA) is a promising target for developing novel chemotherapy agents for tuberculosis, and their inhibitory effects on InhA activity were widely investigated by the physicochemical...
6.
Pakamwong B, Thongdee P, Kamsri B, Phusi N, Kamsri P, Punkvang A, et al.
J Chem Inf Model
. 2022 Mar;
62(7):1680-1690.
PMID: 35347987
DNA gyrase manipulates the DNA topology using controlled breakage and religation of DNA driven by ATP hydrolysis. DNA gyrase has been validated as the enzyme target of fluoroquinolones (FQs), second-line...
7.
Kamsri P, Hanwarinroj C, Phusi N, Pornprom T, Chayajarus K, Punkvang A, et al.
J Chem Inf Model
. 2019 Dec;
60(1):226-234.
PMID: 31820972
The enoyl-acyl carrier protein reductase InhA of is an attractive, validated target for antituberculosis drug development. Moreover, direct inhibitors of InhA remain effective against InhA variants with mutations associated with...
8.
Phusi N, Sato R, Ezawa T, Tomioka S, Hanwarinroj C, Khamsri B, et al.
J Mol Graph Model
. 2019 Mar;
88:299-308.
PMID: 30826710
2-trans enoyl-acyl carrier protein reductase (InhA) has been identified as a promising target for the development of novel chemotherapy for tuberculosis. In the present study, a series of heteroaryl benzamide...